ALACT.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	1.66M
Średni wolumen	58 523.00
Kapitalizacja rynkowa	5.29M
EPS	€0 ( 2023-10-26 )
Następna data zysków	( €0 ) 2024-05-10
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.200
ATR14	€0.0220 (6.47%)

Wolumen Korelacja

Długi: -0.11 (neutral)

Krótki: -0.46 (neutral)

Signal:(37.645) Neutral

Groupe Actiplay SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Groupe Actiplay SA Korelacja - Waluta/Towar

0.67
( moderate )

0.68
( moderate )

0.00
( neutral )

0.57
( weak )

-0.53
( weak negative )

0.02
( neutral )

Groupe Actiplay SA Finanse

Annual	2022
Przychody:	€0
Zysk brutto:	€-86 000.00 (0.00 %)
EPS:	€-1.580

FY	2022
Przychody:	€0
Zysk brutto:	€-86 000.00 (0.00 %)
EPS:	€-1.580

FY	2021
Przychody:	€0.00
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-0.120

FY	2020
Przychody:	€0.00
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-0.726

Financial Reports:

No articles found.

Groupe Actiplay SA

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.